Promoter holding
64.27%
DP
Dhruvi Pharma Private Limited - Due diligence report
A 360° intelligence report on Dhruvi Pharma: trust score, financial health, credit view, compliance, directors, growth and distress signals …
Full Due-Diligence Report + Documents
- Unlock all financial figures & 5-year trends
- Full trust, health & credit-risk scores
- Director details, charges & MCA documents
₹700
₹449
Save ₹251
excl. GST
Or from ₹279/report with credits
View credit packages
Company Credits – Starter
- One credit unlocks this full due-diligence report
- Use across any company’s report, anytime
- Credits valid for 12 months
Choose your own credit amount
View credit packages
Dhruvi Pharma — 360° Intelligence Report
Generated from MCA filings & public records64/100
Trust Score
Moderate
Dhruvi Pharma is assessed as Moderate with a Trust Score of 64/100. Dhruvi Pharma is a private limited indian non-government company incorporated in 2001, operating in the Healthcare sector. The company has shown revenue growth across its recent filed years. It was profitable in its latest filed year. Based on MCA filings and public records, it currently shows a high compliance risk and low financial risk profile.
Report generated on 16 Jul 2026 from the latest processed filings. Dhruvi Pharma Private Limited snapshot & full profile →
Automated indicators derived from public MCA / GST / EPFO records - not a credit rating, not investment, legal or financial advice. Spotted an inaccuracy? Report an error.
02
Score Card
Higher is safer · rule-based & explainableTrust ScoreModerate
64/100
Overall counterparty trust - the headline number of this report.
Compliance ScoreCaution Indicated
10/100
Statutory standing - status, filings, auditor, MSME and litigation.
Financial Health ScoreLow Risk
95/100
Profitability, leverage and liquidity from filed statements.
Credit Risk ScoreLow Risk
95/100
Debt capacity, gearing and security cover for lenders.
Director Stability ScoreLow Risk
95/100
Board strength, DIN status, churn and network.
Growth ScoreLow Risk
85/100
Revenue, profit, asset and hiring momentum.
Distress ScoreModerate
55/100
Early-warning signals - higher means fewer warnings.
03
Financial Intelligence Dashboard
Standalone · 5 filed year(s)Unlock the full 5-year financial dashboard with charts and year-wise figures.
Get full accessScores and observations on this page are already computed from the real filings - only the underlying figures are locked.
04
Credit & Compliance Intelligence
Why the scores are what they are
Credit Risk Score: 95/100 Low Risk
- Liabilities ≈ 38% EBITDA - serviceable.
- No open charges - unencumbered balance sheet.
- Moderate gearing (D/E 1.42).
- Working-capital cover adequate.
- Profitable - internal accruals available.
- Externally credit-rated (A).
Charges position: 0 open (-) · 4 satisfied (57.75 cr).
Banking relationships (from registered charges)
| Lender | Charges | Amount |
|---|---|---|
| Hdfc Bank Limited | 2 | 48.0 cr |
| Yes Bank Limited | 1 | 48.0 cr |
| 3I Infotech Trusteeship Services Limited | 1 | 48.0 cr |
Compliance Score: 10/100 Caution Indicated
- Company status is "Amalgamated" - not Active.
- Last balance sheet is for Mar 2023 - filings overdue.
- Litigation present in 3 court forum(s).
- 3 active GST registration(s).
Legal cases on record (3)
05
Director Intelligence
Stability score: 95/100| Name | DIN / PAN | Designation | Appointed | Tenure | DIN status |
|---|---|---|---|---|---|
| ARVIND KUMAR VENKAT | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| RUPESH HEMENDRA SHAH | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| YASHWANT SINGH | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
| DEEPTIBEN RUPESHBHAI SHAH | 01234567 | Director | 01/04/2018 | 6 yrs | Approved |
- 4 directors on the board.
- No disqualified or deactivated DINs.
- Stable board - no exits in 3 years.
- Average tenure above 5 years.
Director & KMP remuneration (FY 2022)
| Name | Designation | Total remuneration |
|---|---|---|
| A K Sharma | Managing Director | 2.4 cr |
| R Mehta | Whole-time Director | 1.6 cr |
| S Iyer | CFO | 95.0 L |
Remuneration is disclosed in the latest annual return. Unlock full report
06
Ownership & Group Intelligence
As per FY 2022 annual returnPublic / other holding
35.73%
Equity shares
12,45,67,890
Equity paid-up
124.5 cr
Promoters on record
4
Ultimate holding entity
Keimed Private Limited
Subsidiaries
4
Group entities
4
Capital events
1 allotment(s) · 0 transfer(s)
Promoters hold the largest single block of equity - exact percentages are part of the full report.
| Group entity | Relationship | % held |
|---|---|---|
| Anila Medical Private Limited | Subsidiary Company | 74.00% |
| Dhruvi Healthcare Private Limited | Subsidiary Company | 74.00% |
| Yashvi Pharma Private Limited | Subsidiary Company | 74.00% |
| Keimed Private Limited | Holding Company | 74.00% |
| Atc Pharma Private Limited | Subsidiary Company | 74.00% |
Key managerial personnel: RUPESH HEMENDRA SHAH (Managing Director)
Full shareholding pattern, group structure & capital events →
07
Risk Intelligence Center
Growth 85 · Distress 55
Growth signals & trust indicators
Revenue acceleration: +2.1x over 4 year(s).
Latest year revenue grew 24%.
EPFO headcount growing - hiring signal.
Operating for 25+ years.
Active EPFO - real payroll on record.
Active GST registration(s).
Distress signals & risk flags
Statutory filings appear overdue.
Adverse company status: Amalgamated.
Compliance score is weak (10/100).
3 court case(s) on record - see the legal section for details.
08
Stakeholder Verdicts
Vendor · Banker · InvestorVendor due diligence40/100
Caution indicated
Suitability as a supplier / customer counterparty.
- Check the compliance flags before onboarding.
- 2 distress signal(s) - see Risk Center.
- Financial filings available for verification.
Banker assessment74/100
Favourable lending indicators
Indicative lending comfort for banks, NBFCs and trade credit.
- Debt capacity assessed from filed statements.
- No existing security registered - first-charge position available.
- Compliance gaps should be priced into terms.
Investor view83/100
Positive growth indicators
Growth quality and scalability through an investor lens.
- 3 growth signal(s) detected.
- Margin and return trends computable from filings.
- Management team looks stable.
09
MCA Filings & Events Timeline
Latest 15 events01 Sep 2023
Last AGM held
Annual general meeting
03 Aug 2023
Charge satisfied
Hdfc Bank Limited
31 Mar 2023
Latest balance sheet
Filed with ROC
26 Jun 2019
Director ceased
ARVIND KUMAR VENKAT
09 Apr 2019
Securities allotted
7650000 Preference Shares - 7.65 cr raised
13 Jul 2018
Director ceased
YASHWANT SINGH
03 Jul 2018
Director appointed
YASHWANT SINGH (Nominee Director)
15 Sep 2016
Charge created
Hdfc Bank Limited - 1.00 cr
20 May 2015
Charge satisfied
Yes Bank Limited
09 Mar 2015
Director appointed
ARVIND KUMAR VENKAT (Nominee Director)
Director ceased
RUPESH HEMENDRA SHAH
26 Feb 2015
Charge created
Hdfc Bank Limited - 50.00 cr
31 Oct 2011
Charge satisfied
3I Infotech Trusteeship Services Limited
29 Sep 2011
Charge created
Yes Bank Limited - 5.25 cr
20 Nov 2007
Charge created
3I Infotech Trusteeship Services Limited - 1.50 cr
10
Key Observations
Auto-generated from the data aboveRevenue grew 0.86 over the last 4 financial year(s).
Net profit margin moved from 61% to 38%.
Debt-to-equity stands at 1.42 - manageable leverage.
Net worth is positive.
4 active director(s) / partner(s); board looks stable and experienced.
3 active GST registration(s) indicate ongoing business operations.
All 4 registered charge(s) stand satisfied - past borrowings repaid.
Operates a group structure with 4 subsidiary(ies) - assess on a consolidated basis.
Carries an external credit rating of A from Care.
EPFO-registered employer - verifiable payroll history exists.
Promoters hold the largest single block of equity as per the FY 2022 annual return.
Director / KMP remuneration is disclosed in the latest annual return - exact figures available in the full report.
Capital has been raised through 1 security allotment(s) - amounts available in the full report.
| Company | CIN | Location |
|---|---|---|
| S.B. Markplus Private Limited | U51909DL2012PTC232660 | Dilshad Garden, Delhi, India |
| Bharat Steels Chennai | U51420TN2004PTC052470 | Chennai, Tamil Nadu, India |
| Dml Exim Private Limited | U55100GJ1988PTC011223 | Rajkot, Gujarat, India |
| Ssk Exports Ltd. | U51909WB1993PLC058533 | Kol, West Bengal, India |
| Bavtawala Iron And Steels Private Limited | U99999MH1996PTC103834 | Mumbai, Maharashtra, India |
| Shakti Agencies Private Limited | U51398OR1998PTC005467 | Bhubaneswar, Orissa, India |
| Sree Sirisai Traders Private Limited | U51101TG2012PTC080745 | Hyderabad, Telangana, India |
| Arvindfashions | U52100GJ2020PTC112995 | Ahmedabad, Gujarat, India |
12
Who Uses This Report
CA · CS · Banker · Investor · VendorChartered Accountants (CA)
Verify Dhruvi Pharma before audits and certifications: compliance score 10/100, filing history, auditor history and charge records in one place - instead of pulling each MCA form separately.
Company Secretaries (CS)
Track statutory health of Dhruvi Pharma: ACTIVE compliance status, annual-return recency, director DIN status, board churn and the events timeline - the inputs for secretarial audits and due-diligence certificates.
Bankers & NBFCs
Current banker verdict: Favourable lending indicators. Credit risk score 95/100, existing charge position and lender relationships - a first-pass credit memo before formal appraisal.
Investors & Analysts
Investor view: Positive growth indicators. Growth score 85/100, margin trends, ownership structure and peer set for Dhruvi Pharma - screening before a deeper diligence.
Vendors & Procurement Teams
Vendor verdict: Caution indicated. Trust score 64/100, distress signals and MSME payment-delay disclosures - know whether Dhruvi Pharma pays its suppliers before you extend credit terms.
Lawyers & Compliance Teams
Litigation footprint (3 case(s) on record), regulatory flags, charge documents trail and director networks for Dhruvi Pharma - groundwork for KYC, onboarding and disputes.
13
Frequently Asked Questions
Is Dhruvi Pharma an active company?
Dhruvi Pharma has MCA status “Amalgamated” with a compliance score of 10/100 (Caution Indicated).
Is Dhruvi Pharma financially healthy?
Dhruvi Pharma has a Financial Health Score of 95/100 (Low Risk) based on its filed financial statements.
Should I do business with Dhruvi Pharma?
Its overall Trust Score is 64/100 (Moderate). Vendor verdict: Caution indicated. Review the risk flags in the Risk Intelligence Center before deciding.
Who controls Dhruvi Pharma?
The ultimate holding entity is Keimed Private Limited. 4 active director(s) are on record.
Does Dhruvi Pharma have loans or charges against its assets?
No open charges - all 4 registered charge(s) stand satisfied, indicating past borrowings were repaid.
Is Dhruvi Pharma up to date with its ROC filings?
Last balance sheet is for Mar 2023 - filings overdue. Overall compliance score: 10/100 (Caution Indicated).
Is it risky to lend to Dhruvi Pharma?
Its Credit Risk Score is 95/100 (Low Risk). Banker verdict: Favourable lending indicators.
Disclaimer: This report is generated automatically from MCA filings and public records as available
in our system at the time of the last update. Scores, bands and verdicts are rule-based derived indicators of the
underlying data - they are opinions generated by an algorithm, not statements of fact about the company, and are
not credit ratings (within the meaning of SEBI regulations), audits, or investment, legal or financial advice.
Verify from official sources and consult a qualified professional before any business, lending or investment decision.
If you represent this company and believe any information is inaccurate or outdated,
report it here and we will review promptly.
